Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD, PrecisionCHD and the HeartRisk population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
The company’s participation underscores the growing importance of precision medicine in managing chronic diseases that significantly impact employer healthcare spending. Cardiovascular disease remains the leading cause of death globally and a major contributor to rising health insurance premiums and lost productivity. According to the press release, the AI-powered tests leverage a proprietary Integrated Genetic-Epigenetic Engine to provide personalized risk assessments, potentially enabling earlier interventions that could reduce costly events like heart attacks and strokes.
For benefits decision-makers, the ability to stratify employee populations by cardiovascular risk could lead to more targeted wellness programs and better allocation of healthcare resources. The HeartRisk platform offers population-level insights, allowing plan administrators to identify high-risk groups and tailor interventions. This approach aligns with a broader trend in employer-sponsored health plans toward value-based care and data-driven cost containment.
The conferences provide a platform for Cardio Diagnostics to demonstrate how its technology can be integrated into existing benefits structures. The company aims to show that earlier detection of heart disease risk can lower long-term medical expenses and improve employee health outcomes, which is particularly relevant as employers seek ways to manage post-pandemic healthcare costs.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging its AI-driven Core Technology for cardiovascular disease.
For more information, visit the company’s newsroom at https://ibn.fm/CDIO. The full press release is available at https://ibn.fm/qFRHu.
